This compound is a conjugated form of the antimitotic agent monomethyl auristatin E (MMAE), linked through a maleimidocaproyl-valine-citrulline-p-aminobenzylcarbamate (mc-vc-PAB) spacer. It is primarily used as an intermediate in the manufacturing of antibody-drug conjugates (ADCs), enabling the stable attachment of the cytotoxic payload to targeting antibodies.
콘텐츠 범위: 이 페이지의 정보는 화학물질 식별 및 산업 공급·연구개발·제조 맥락을 대상으로 합니다. 치료 효능 주장, 의료 조언 또는 의약품 사용 지침에 해당하지 않습니다.
이 화합물을 구매하거나 공급하시겠습니까?
재고를 등록하거나 구매 요청을 게시하세요
CAS 646502-53-6
L-Valinamide, N,N-dimethyl-L-valyl-N-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1R,2S)-2-hydro xy-1-methyl-
active pharmaceutical ingredient
MMAF
pharmaceutical intermediate
VC-PAB-MMAE
antibody-drug conjugate intermediate
N-(2-BROMO-4,5-DIFLUOROPHENYL)ACETAMIDE
pharmaceutical intermediate
2-azaspiro[4.5]decan-3-one
Pharmaceutical intermediate
1-Bromo-2-methoxyethane
pharmaceutical intermediate
(S)-(+)-2-PHENYLGLYCINE AMIDE
Peptide building block intermediate
Monomethyl auristatin E
pharmaceutical intermediate for antibody-drug conjugate
(2S)-N-[(2S)-1-[[(3R,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamide
DASWEROEPLKSEI-AWNAIHLBSA-N
CC[C@H](C)C([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)N[C@H](C)[C@H](C2=CC=CC=C2)O)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC